vimarsana.com

Latest Breaking News On - Aurinia pharmaceuticals inc stock exchange - Page 1 : vimarsana.com

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with. | June 20, 2023

United statesWei kyAurinia pharmaceuticalsMeeting of the european renal associationAurinia pharmaceuticals incAnnual meetingEuropean renal associationRed cell aplasiaDrug interactionsModerate hepatic impairmentPrescribing informationBoxed warningMedication guideEuropean renal associate annual meetingAurinia pharmaceuticals inc stock exchangePress release

Aurinia Pharmaceuticals : Jefferies Healthcare Conference June 2023

Corporate Presentation Jefferies Healthcare Conference June 8, 2023 Cautionary statement. | June 8, 2023

United statesExchange commission electronic document gatheringAnnual reportCanadian securities administrator systemElectronic document analysisExchange commissionElectronic document gatheringRetrieval systemAurinia pharmaceuticals inc stock exchangePress releaseAutionary auph ca05156v1022

Aurinia Pharmaceuticals Inc - LUPKYNIS Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

EDMONTON - Aurinia Pharmaceuticals Inc. today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, which found that LUPKYNIS with. | June 2, 2023

United statesGreg keenanEmily littlejohnAndrea christopherAurinia pharmaceuticals incEuropean congressAurinia pharmaceuticalsCleveland clinic main campusImmunologic diseaseChief medical officerRed cell aplasiaDrug interactionsModerate hepatic impairmentNews publishingAurinia pharmaceuticals inc stock exchangePress release

LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

Aurinia Pharmaceuticals Inc. today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, which found that LUPKYNIS® with mycophenolate. | June 1, 2023

United statesEmily littlejohnGreg keenanAurinia pharmaceuticalsEuropean congressAurinia pharmaceuticals incCleveland clinic main campusImmunologic diseaseChief medical officerRed cell aplasiaDrug interactionsModerate hepatic impairmentPrescribing informationBoxed warningMedication guideAurinia pharmaceuticals inc stock exchange

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Pharmaceuticals Inc. today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission . Under U.S. federal securities laws,. | May 26, 2023

United statesAurinia pharmaceuticals incAurinia pharmaceuticalsExchange commissionUnited states securitiesSecurities actNasdaq listing ruleAurinia pharmaceuticals inc stock exchangePress releaseEcurities auph ca05156v1022

vimarsana © 2020. All Rights Reserved.